Angela Gutowski
Nurse Practitioner · Hamilton, OHNPI 1225517444
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 631 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,718, 2.3 times the $1,625 reported in 2021. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 631 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$942
- Lundbeck LLC$829
- AbbVie$799
- plus $3K from 15 others
What the payments were for
- Food & beverage$10,218100%
- Education$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 86 | $1,954 |
| Alkermes, Inc. | 92 | $1,436 |
| Otsuka America Pharmaceutical, Inc. | 64 | $1,101 |
| Johnson & Johnson | 38 | $942 |
| Lundbeck LLC | 66 | $829 |
| AbbVie | 88 | $799 |
| Neurocrine Biosciences, Inc. | 37 | $664 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $588 |
| Vanda Pharmaceuticals Inc. | 21 | $528 |
| Sunovion Pharmaceuticals Inc. | 50 | $435 |
| Luye Pharma (USA) Ltd. | 7 | $167 |
| E.r. Squibb & Sons, L.L.C. | 14 | $165 |
| Axsome Therapeutics, Inc. | 7 | $140 |
| Idorsia Pharmaceuticals US Inc | 4 | $136 |
| Corium, LLC | 8 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Indivior Inc. | 2 | $32 |
| Merck | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 2 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,468
- ARISTADA$500
- Austedo XR$364
- REXULTI$362
- AUSTEDO$253
- ARISTADA INITIO$125
- INVEGA SUSTENNA$124
- QUVIVIQ$122
- UZEDY$121
- ERZOFRI EXTENDED-RELEASE$121
- Fanapt$104
How this compares
$10,256 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 68 | $219,948 |
| IngrezzaValbenazine Tosylate | 20 | $175,828 |
| Abilify MaintenaAripiprazole | 49 | $145,791 |
| Austedo XrDeutetrabenazine | 11 | $130,602 |
| AristadaAripiprazole Lauroxil | 24 | $92,414 |
| RexultiBrexpiprazole | 45 | $87,904 |
| VraylarCariprazine Hcl | 45 | $73,330 |
| TrintellixVortioxetine Hydrobromide | 52 | $40,122 |
| Lurasidone Hcl | 54 | $15,535 |
| QelbreeViloxazine Hcl | 11 | $7,996 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 53 | $5,903 |
| Aripiprazole | 127 | $5,128 |
| Ziprasidone Hcl | 17 | $4,441 |
| Olanzapine | 106 | $3,827 |
| Olanzapine OdtOlanzapine | 33 | $3,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,101 | $233,69594 claims |
| Johnson & JohnsonInvega Sustenna | $942 | $219,94868 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $664 | $175,82820 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Loxapine | $1,954 | $131,73224 claims |
| Alkermes, Inc.Aristada | $1,436 | $92,41424 claims |
| AbbVieVraylar | $799 | $73,33045 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $82 | $40,12252 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $47 | $7,99611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Hamilton
- Peggy ClarkHamilton$26K
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.